Microdose, Author at Microdose

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Press Releases

15 Apr 2021

Tryp Therapeutics to Host Investor Day on April 22

San Diego, California–(Newsfile Corp....

By Microdose

Press Releases

14 Apr 2021

Psyched Wellness Receives DTC Eligibility

Toronto, Ontario–(Newsfile Corp....

By Microdose

Press Releases

12 Apr 2021

Lobe Sciences to Present at the Emerging Growth Conference on April 14, 2021

By Microdose

Press Releases

7 Apr 2021

New Wave Subsidiary, Way of Will Inc., Confirms Plans to Expand Brand Presence on Walmart.com

TORONTO, April 7, 2021 /CNW/ – NEW WAVE HOLDINGS CORP....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

6 Apr 2021

Lobe Sciences Appoints Ilan Hayman to Advisory Board

Vancouver, British Columbia–(Newsfile Corp....

By Microdose

Press Releases

6 Apr 2021

NeonMind Developing Music Playlist for Psychedelic Therapy Sessions

Vancouver, British Columbia–(Newsfile Corp....

By Microdose

Press Releases

5 Apr 2021

Tryp Therapeutics Announces Listing on OTCQB and DTC Eligibility

San Diego, California–(Newsfile Corp....

By Microdose

Press Releases

1 Apr 2021

Mindset Pharma Announces Filing of Amended and Restated FS and MD&A for the Three and Six Month Period Ended December 31, 2020

Toronto, Ontario–(Newsfile Corp....

By Microdose

Press Releases

1 Apr 2021

Tryp Therapeutics Announces Amendment to Option Plan and Option Grant

San Diego, California–(Newsfile Corp....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts

WordPress Ads

No Result

View All Result

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Press Releases

Tryp Therapeutics to Host Investor Day on April 22

Press Releases

Psyched Wellness Receives DTC Eligibility

Press Releases

Lobe Sciences to Present at the Emerging Growth Conference on April 14, 2021

Press Releases

New Wave Subsidiary, Way of Will Inc., Confirms Plans to Expand Brand Presence on Walmart.com

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

Lobe Sciences Appoints Ilan Hayman to Advisory Board

Press Releases

NeonMind Developing Music Playlist for Psychedelic Therapy Sessions

Press Releases

Tryp Therapeutics Announces Listing on OTCQB and DTC Eligibility

Press Releases

Mindset Pharma Announces Filing of Amended and Restated FS and MD&A for the Three and Six Month Period Ended December 31, 2020

Press Releases

Tryp Therapeutics Announces Amendment to Option Plan and Option Grant

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

Delix Therapeutics Reports Strong Phase Ib Results

Childhood Trauma’s Role in Men’s Substance Use Disorders

Human-Centered AI in Healthcare

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch